7 Hills Pharma

7 Hills Pharma is a clinical-stage company advancing first-in-class small molecules designed to safely improve the efficacy of cancer immunotherapies with no added toxicity. Its platform molecules leverage a novel mechanism of action, selective allosteric integrin activation, that was pioneered by its co-founders. Backed by >$17MM in state and federal grants, its lead oncology molecule, alintegimod, is undergoing a Phase Ib/IIa clinical trial in combination with dual immune checkpoint blockade for the treatment of aPD-1-resistant solid tumors. Supported by $4.7MM in additional grant awards, 7HP935, its lead molecule to augment cell/gene therapies, is progressing through IND-enabling studies.